株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の子宮頸癌検査市場および患者の予測:ラップスメア、HPV DNA、VIA

Global Cervical Cancer Screening Market & Patients, By Test Type (Pap Smear, HPV DNA, VIA) Forecast

発行 Renub Research 商品コード 298601
出版日 ページ情報 英文 238 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=112.82円で換算しております。
Back to Top
世界の子宮頸癌検査市場および患者の予測:ラップスメア、HPV DNA、VIA Global Cervical Cancer Screening Market & Patients, By Test Type (Pap Smear, HPV DNA, VIA) Forecast
出版日: 2017年02月07日 ページ情報: 英文 238 Pages
概要

世界の子宮頸癌市場規模は、2020年までに約70億米ドルに達すると予測されています。北米は子宮頸癌市場の約50%を支配し、米国と日本で50%以上の市場シェアを構成しています。欧州地域では、英国とフランスが同市場の上位2ヶ国となっています。アジアは子宮頸癌検査人口で最大のシェアを保有しています。

当レポートは、世界の子宮頸癌検査市場について調査し、子宮頸癌検査人口と予測、子宮頸癌の死亡率、検査別(ラップスメア・HPV DNA・VIA)の市場予測、および主要国の市場予測などを提供しています。

第1章 エグゼクティブサマリー

第2章 世界の子宮頸癌検査(スクリーニング)人口・予測

  • アジアの子宮頸癌検査(スクリーニング)人口・予測
  • 欧州の子宮頸癌検査(スクリーニング)人口・予測
  • 北米の子宮頸癌検査(スクリーニング)人口・予測

第3章 世界の子宮頸癌検査(スクリーニング)市場・予測

  • パップスメア検査(スクリーニング)市場・予測
  • HPV DNA検査(スクリーニング)市場・予測
  • 酢酸(VIA)検査(スクリーニング)による子宮頸癌の目視検査市場・予測

第4章 世界の子宮頸癌検査(スクリーニング)市場分析:地域別

  • アジアの子宮頸癌検査(スクリーニング)市場・予測
  • 欧州の子宮頸癌検査(スクリーニング)市場・予測
  • 北米の子宮頸癌検査(スクリーニング)市場・予測

第5章 世界の子宮頸癌検査(スクリーニング)人口シェア・予測

  • 地域別:世界の子宮頸癌検査(スクリーニング)人口シェア・予測
  • 国別:世界の子宮頸癌検査(スクリーニング)人口、国別のシェア・予測

第6章 世界の子宮頸癌検査(スクリーニング)市場シェア・予測

  • 地域別:世界の子宮頸癌検査(スクリーニング)市場シェア・予測
  • 国別:世界の子宮頸癌検査(スクリーニング)市場シェア・予測
  • 国別:世界のパップスメア検査(スクリーニング)市場シェア・予測
  • 国別:世界のHPV DNA検査(スクリーニング)市場シェア・予測
  • 国別:世界のVIA検査(スクリーニング)市場シェア・予測

第7章 英国:子宮頸癌検査分析

  • 子宮頸癌検査(スクリーニング)人口
    • パップスメア検査人口&予測
    • HPV DNA検査人口&予測
  • 子宮頸癌死亡率
  • 子宮頸癌検査(スクリーニング)分析
    • 子宮頸癌検査市場&予測
    • パップスメア検査市場・予測
    • HPV DNA検査市場・予測

第8章 フランス

第9章 ドイツ

第10章 イタリア

第11章 スペイン

第12章 スウェーデン

第13章 スイス

第14章 ノルウェー

第15章 オランダ

第16章 米国

第17章 カナダ

第18章 日本

第19章 韓国

第20章 シンガポール

第21章 マレーシア

第22章 インド

第23章 中国

第24章 タイ

第25章 インドネシア

第26章 子宮頸癌市場の成長促進因子

第27章 子宮頸癌市場における課題

図表リスト

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

‘Global Cervical Cancer Screening Market & Patients, By Test Type (Pap Smear, HPV DNA, VIA) Forecast ’ is a 238 page market research report with 245 Figures and 15 Tables. Global Cervical Market is expected to be close to US$ 7 Billion by 2020. North America controls almost 50 percent Cervical Cancer Market. United States and Japan together makes more than 50 percent market share. In Europe region, United Kingdom and France are other top two leading countries in this market place. Asia has highest share in cervical cancer screening population. Indonesia, China and India are top three countries having largest cervical cancer test population in Asia. In the study we have found that Japan market will steadily decline over forecast period.

The report published by Renub Research provides a complete analysis of top 20 Countries Cervical Cancer Test 1) Market, 2)Population & 3)Mortality.

These 3 points have been further sub divided into following segments.

1. Cervical Cancer Test Market (2008 - 2020)

  • Pap Smear Test Market (2008 - 2020)
  • HPV DNA Test Market (2008 - 2020)
  • VIA Test Market (2008 - 2020)

2. Cervical cancer Test Population (2008 - 2020)

  • Pap Smear Test Population (2008 - 2020)
  • HPV DNA Test Population (2008 - 2020)
  • VIA Test Population (2008 - 2020)

3. Cervical Cancer Mortality Population (2001 - 2011)

All the 20 Countries Studied in the Report are as Follows

  • 1. United Kingdom
  • 2. France
  • 3. Germany
  • 4. Italy
  • 5. Spain
  • 6. Sweden
  • 7. Switzerland
  • 8. Norway
  • 9. Netherlands
  • 10. United States
  • 11. Canada
  • 12. Japan
  • 13. Korea
  • 14. Singapore
  • 15. Malaysia
  • 16. Australia
  • 17. India
  • 18. China
  • 19. Thailand
  • 20. Indonesia

Key Questions Answered in the Report?

  • What is Global Cervical Cancer Screening Market, Forecast and by Countries??
  • What is Global Pap Smear Screening Market and by Countries?
  • What is Global HPV DNA Screening Market, Forecast and by Countries??
  • What is Global Visual Inspection with Acetic Acid (VIA) Screening Market, Forecast and by Countries?
  • What is Cervical Cancer Screening Market in Asia, Europe and North America?
  • What is Cervical Cancer Screening Population in North America, Asia and Europe?

Table of Contents

1. Executive Summary

2. Global Cervical Cancer Test (Screening) Population & Forecast

  • 2.1. Asia Cervical Cancer Test (Screening) Population & Forecast
  • 2.2. Europe Cervical Cancer Test (Screening) Population & Forecast
  • 2.3. North America Cervical Cancer Test (Screening) Population & Forecast

3. Global Cervical Cancer Test (Screening) Market & Forecast

  • 3.1. Global Cervical Cancer Pap Smear Test (Screening) Market & Forecast
  • 3.2. Global Cervical Cancer HPV DNA Test (Screening) Market & Forecast
  • 3.3. Global - Cervical Cancer Visual Inspection with Acetic Acid (VIA) Test (Screening) Market & Forecast

4. By Region - Global Cervical Cancer Test (Screening) Market Analysis

  • 4.1. Asia Cervical Cancer Test (Screening) Market & Forecast
  • 4.2. Europe Cervical Cancer Test (Screening) Market & Forecast
  • 4.3. North America Cervical Cancer Test (Screening) Market & Forecast

5. Global Cervical Cancer Test (Screening) Population Share & Forecast

  • 5.1. By Region - Global Cervical Cancer Test (Screening) Population Share & Forecast
  • 5.2. By Countries - Global Cervical Cancer Test (Screening) Population Country Share & Forecast

6. Global Cervical Cancer Test (Screening) Market Share & Forecast

  • 6.1. By Region - Global Cervical Cancer Test (Screening) Market Share & Forecast
  • 6.2. By Countries - Global Cervical Cancer Test (Screening) Market Share & Forecast
  • 6.3. By Countries - Global Pap Smear Test (Screening) Market Share & Forecast
  • 6.4. By Countries - Global HPV DNA Test (Screening) Market Share & Forecast
  • 6.5. By Countries - Global VIA Test (Screening) Market Share & Forecast

7. United Kingdom - Cervical Cancer Test Analysis

  • 7.1. United Kingdom Cervical Cancer Test (Screening) Population
    • 7.1.1. United Kingdom Cervical Cancer Pap Smear Test Population & Forecast
    • 7.1.2. United Kingdom Cervical Cancer HPV DNA Test Population & Forecast
  • 7.2. United Kingdom Cervical Cancer Deaths
  • 7.3. United Kingdom Cervical Cancer Test (Screening) Analysis
    • 7.3.1. United Kingdom Cervical Cancer Test Market & Forecast
    • 7.3.2. United Kingdom Pap Smear Test Market & Forecast
    • 7.3.3. United Kingdom HPV DNA Test Market & Forecast

8. France - Cervical Cancer Test Analysis

  • 8.1. France Cervical Cancer Test (Screening) Population
    • 8.1.1. France Cervical Cancer Pap Smear Test Population & Forecast
    • 8.1.2. France Cervical Cancer HPV DNA Test Population & Forecast
  • 8.2. France Cervical Cancer Mortality
  • 8.3. France Cervical Cancer Test (Screening) Analysis
    • 8.3.1. France Cervical Cancer Test Market & Forecast
    • 8.3.2. France Pap Smear Test Market & Forecast
    • 8.3.3. France HPV DNA Test Market & Forecast

9. Germany - Cervical Cancer Test Analysis

  • 9.1. Germany Cervical Cancer Test (Screening) Population
    • 9.1.1. Germany Cervical Cancer Pap Smear Test Population & Forecast
    • 9.1.2. Germany Cervical Cancer HPV DNA Test Population & Forecast
  • 9.2. Germany Cervical Cancer Mortality
  • 9.3. Germany Cervical Cancer Test (Screening) Market
    • 9.3.1. Germany Cervical Cancer Test Market & Forecast
    • 9.3.2. Germany Pap Smear Test Market & Forecast
    • 9.3.3. Germany HPV DNA Test Market & Forecast

10. Italy - Cervical Cancer Test Analysis

  • 10.1. Italy Cervical Cancer Test (Screening) Population
    • 10.1.1. Italy Cervical Cancer Pap Smear Test Population & Forecast
    • 10.1.2. Italy Cervical Cancer HPV DNA Test Population & Forecast
  • 10.2. Italy Cervical Cancer Mortality
  • 10.3. Italy Cervical Cancer Test (Screening) Market
    • 10.3.1. Italy Cervical Cancer Test Market & Forecast
    • 10.3.2. Italy Pap Smear Test Market & Forecast
    • 10.3.3. Italy HPV DNA Test Market & Forecast

11. Spain - Cervical Cancer Test Analysis

  • 11.1. Spain Cervical Cancer Test (Screening) Population
    • 11.1.1. Spain Cervical Cancer Pap Smear Test Population & Forecast
    • 11.1.2. Spain Cervical Cancer HPV DNA Test Population & Forecast
  • 11.2. Spain Cervical Cancer Mortality
  • 11.3. Spain Cervical Cancer Test (Screening) Market
    • 11.3.1. Spain Cervical Cancer Test Market & Forecast
    • 11.3.2. Spain Pap Smear Test Market & Forecast
    • 11.3.3. Spain HPV DNA Test Market & Forecast

12. Sweden - Cervical Cancer Test Analysis

  • 12.1. Sweden Cervical Cancer Test (Screening) Population
    • 12.1.1. Sweden Cervical Cancer Pap Smear Test Population & Forecast
    • 12.1.2. Sweden Cervical Cancer HPV DNA Test Population & Forecast
  • 12.2. Sweden Cervical Cancer Mortality
  • 12.3. Sweden Cervical Cancer Test (Screening) Market
    • 12.3.1. Sweden Cervical Cancer Test Market & Forecast
    • 12.3.2. Sweden Pap Smear Test Market & Forecast
    • 12.3.3. Sweden HPV DNA Test Market & Forecast

13. Switzerland - Cervical Cancer Test Analysis

  • 13.1. Switzerland Cervical Cancer Test (Screening) Population
    • 13.1.1. Switzerland Cervical Cancer Pap Smear Test Population & Forecast
    • 13.1.2. Switzerland Cervical Cancer HPV DNA Test Population & Forecast
  • 13.2. Switzerland Cervical Cancer Mortality
  • 13.3. Switzerland Cervical Cancer Test (Screening) Market
    • 13.3.1. Switzerland Cervical Cancer Test Market & Forecast
    • 13.3.2. Switzerland Pap Smear Test Market & Forecast
    • 13.3.3. Switzerland HPV DNA Test Market & Forecast

14. Norway - Cervical Cancer Test Analysis

  • 14.1. Norway Cervical Cancer Test (Screening) Population
    • 14.1.1. Norway Cervical Cancer Pap Smear Test Population & Forecast
    • 14.1.2. Norway Cervical Cancer HPV DNA Test Population & Forecast
  • 14.2. Norway Cervical Cancer Mortality
  • 14.3. Norway Cervical Cancer Test (Screening) Market
    • 14.3.1. Norway Cervical Cancer Test Market & Forecast
    • 14.3.2. Norway Pap Smear Test Market & Forecast
    • 14.3.3. Norway HPV DNA Test Market & Forecast

15. Netherlands - Cervical Cancer Test Analysis

  • 15.1. Netherlands Cervical Cancer Test (Screening) Population
    • 15.1.1. Netherlands Cervical Cancer Pap Smear Test Population & Forecast
    • 15.1.2. Netherlands Cervical Cancer HPV DNA Test Population & Forecast
  • 15.2. Netherlands Cervical Cancer Mortality
  • 15.3. Netherlands Cervical Cancer Test (Screening) Market
    • 15.3.1. Netherlands Cervical Cancer Test Market & Forecast
    • 15.3.2. Netherlands Pap Smear Test Market & Forecast
    • 15.3.3. Netherlands HPV DNA Test Market & Forecast

16. United States - Cervical Cancer Test Analysis

  • 16.1. United States Cervical Cancer Test (Screening) Population
    • 16.1.1. United States Cervical Cancer Pap Smear Test Population & Forecast
    • 16.1.2. United States Cervical Cancer HPV DNA Test Population & Forecast
  • 16.2. United States Cervical Cancer Mortality
  • 16.3. United States Cervical Cancer Test (Screening) Market
    • 16.3.1. United States Cervical Cancer Test Market & Forecast
    • 16.3.2. United States Pap Smear Test Market & Forecast
    • 16.3.3. United States HPV DNA Test Market & Forecast

17. Canada - Cervical Cancer Test Analysis

  • 17.1. Canada Cervical Cancer Test (Screening) Population
    • 17.1.1. Canada Cervical Cancer Pap Smear Test Population & Forecast
    • 17.1.2. Canada Cervical Cancer HPV DNA Test Population & Forecast
  • 17.2. Canada Cervical Cancer Mortality
  • 17.3. Canada Cervical Cancer Test (Screening) Market
    • 17.3.1. Canada Cervical Cancer Test Market & Forecast
    • 17.3.2. Canada Pap Smear Test Market & Forecast
    • 17.3.3. Canada HPV DNA Test Market & Forecast

18. Japan - Cervical Cancer Test Analysis

  • 18.1. Japan Cervical Cancer Test (Screening) Population
    • 18.1.1. Japan Cervical Cancer Pap Smear Test Population & Forecast
    • 18.1.2. Japan Cervical Cancer HPV DNA Test Population & Forecast
  • 18.2. Japan Cervical Cancer Mortality
  • 18.3. Japan Cervical Cancer Test (Screening) Market
    • 18.3.1. Japan Cervical Cancer Test Market & Forecast
    • 18.3.2. Japan Pap Smear Test Market & Forecast
    • 18.3.3. Japan HPV DNA Test Market & Forecast

19. South Korea - Cervical Cancer Tests Analysis

  • 19.1. South Korea - Cervical Cancer Test (Screening) Population
    • 19.1.1. South Korea - Cervical Cancer Pap Smear Test Population & Forecast
    • 19.1.2. Korea Cervical Cancer HPV DNA Test Population & Forecast
  • 19.2. Korea Cervical Cancer Mortality
  • 19.3. Korea Cervical Cancer Test (Screening) Market
    • 19.3.1. Korea Cervical Cancer Test Market & Forecast
    • 19.3.2. Korea Pap Smear Test Market & Forecast
    • 19.3.3. Korea HPV DNA Test Market & Forecast

20. Singapore - Cervical Cancer Tests Analysis

  • 20.1. Singapore - Cervical Cancer Test (Screening) Population
    • 20.1.1. Singapore - Cervical Cancer Pap Smear Test Population & Forecast
    • 20.1.2. Singapore Cervical Cancer HPV DNA Test Population & Forecast
  • 20.2. Singapore Cervical Cancer Test (Screening) Market
    • 20.2.1. Singapore Cervical Cancer Test Market & Forecast
    • 20.2.2. Singapore Pap Smear Test Market & Forecast
    • 20.2.3. Singapore HPV DNA Test Market & Forecast

21. Malaysia - Cervical Cancer Test Analysis

  • 21.1. Malaysia - Cervical Cancer Test (Screening) Population
    • 21.1.1. Malaysia Cervical Cancer Pap Smear Test Population & Forecast
    • 21.1.2. Malaysia Cervical Cancer HPV DNA Test Population & Forecast
  • 21.2. Malaysia Cervical Cancer Test (Screening) Market
    • 21.2.1. Malaysia Cervical Cancer Test Market & Forecast
    • 21.2.2. Malaysia Pap Smear Test Market & Forecast
    • 21.2.3. Malaysia HPV DNA Test Market & Forecast

22. India - Cervical Cancer Test Analysis

  • 22.1. India - Cervical Cancer Test (Screening) Population
    • 22.1.1. India Cervical Cancer Pap Smear Test Population & Forecast
    • 22.1.2. India Cervical Cancer HPV DNA Test Population & Forecast
    • 22.1.3. India Cervical Cancer VIA Test Population & Forecast
  • 22.2. India Cervical Cancer Test (Screening) Market
    • 22.2.1. India Cervical Cancer Test Market & Forecast
    • 22.2.2. India Pap Smear Test Market & Forecast
    • 22.2.3. India HPV DNA Test Market & Forecast
    • 22.2.4. India VIA Test Market & Forecast

23. China - Cervical Cancer Test Analysis

  • 23.1. China - Cervical Cancer Test (Screening) Population
    • 23.1.1. China Cervical Cancer Pap smear Test Population & Forecast
    • 23.1.2. China Cervical Cancer HPV DNA Test Population & Forecast
    • 23.1.3. China Cervical Cancer VIA Test Population & Forecast
  • 23.2. China - Cervical Cancer Test (Screening) Market
    • 23.2.1. China Cervical Cancer Test Market & Forecast
    • 23.2.2. China Pap Smear Test Market & Forecast
    • 23.2.3. China HPV DNA Test Market & Forecast
    • 23.2.4. China VIA Test Market & Forecast

24. Thailand - Cervical Cancer Test Analysis

  • 24.1. Thailand - Cervical Cancer Test (Screening) Population
    • 24.1.1. Thailand Cervical Cancer Pap Smear Test Population & Forecast
    • 24.1.2. Thailand Cervical Cancer VIA Test Population & Forecast
  • 24.2. Thailand Cervical Cancer Test (Screening) Market
    • 24.2.1. Thailand Cervical Cancer Test Market & Forecast
    • 24.2.2. Thailand Pap smear Test Market & Forecast
    • 24.2.3. Thailand VIA Test Market & Forecast

25. Indonesia - Cervical Cancer Test Analysis

  • 25.1. Indonesia Cervical Cancer Test (Screening) Population
    • 25.1.1. Indonesia Cervical Cancer Pap Smear Test Population & Forecast
    • 25.1.2. Indonesia Cervical Cancer HPV DNA Test Population & Forecast
    • 25.1.3. Indonesia Cervical Cancer VIA Test Population & Forecast
    • 25.1.4. Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Population & Forecast
  • 25.2. Indonesia Cervical Cancer Test (Screening) Market
    • 25.2.1. Indonesia Cervical Cancer Test Market & Forecast
    • 25.2.2. Indonesia Pap smear Test Market & Forecast
    • 25.2.3. Indonesia HPV DNA Test Market & Forecast
    • 25.2.4. Indonesia VIA Test Market & Forecast
    • 25.2.5. Indonesia Cervical Cancer Both (Pap Smear & VIA) Test Market & Forecast

26. Cervical Cancer Test Market Growth Drivers

  • 26.1. Introduction of Low Cost VIA Test
    • 26.1.1. Countries Offering VIA Test via National Programs
    • 26.1.2. Countries Offering VIA Test via Pilot Programs
  • 26.2. Worldwide High Prevalence of HPV Infected Patients
  • 26.3. Rising Number of Incidence of Cervical Cancer in United Kingdom
  • 26.4. Worldwide Rising Incidence of Teenage Sexual Cases

27. Challenges in Cervical Cancer Test Market

  • 27.1. Lack of Appropriate Healthcare Infrastructure
  • 27.2. Introduction of HPV Vaccination Programs Worldwide

List of Figures:

  • Figure 2-1: Global-Cervical Cancer Test Population (Million), 2008-2015
  • Figure 2-2: Global-Forecast for Cervical Cancer Test Population (Million), 2016-2020
  • Figure 2-3: Asia-Cervical Cancer Test Population (Million), 2008-2015
  • Figure 2-4: Asia-Forecast for Cervical Cancer Test Population (Million), 2016-2020
  • Figure 2-5: Europe-Cervical Cancer Test Population (Million), 2008-2015
  • Figure 2-6: Europe-Forecast for Cervical Cancer Test Population (Million), 2016-2020
  • Figure 2-7: North America-Cervical Cancer Test Population (Million), 2008-2015
  • Figure 2-8: North America-Forecast for Cervical Cancer Test Population (Million), 2016-2020
  • Figure 3-1: Global-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 3-2: Global-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 3-3: Global-Cervical Cancer Pap Smear Test Market (Million US$), 2008-2015
  • Figure 3-4: Global-Forecast for Cervical Cancer Pap Smear Test Market (Million US$), 2016-2020
  • Figure 3-5: Global-Cervical Cancer HPV DNA Test Market (Million US$), 2008-2015
  • Figure 3-6: Global-Forecast for Cervical Cancer HPV DNA Test Market (Million US$), 2016-2020
  • Figure 3-7: Global-Cervical Cancer VIA Test Market (Million US$), 2008-2015
  • Figure 3-8: Global-Forecast for Cervical Cancer VIA Test Market (Million US$), 2016-2020
  • Figure 4-1: Asia-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 4-2: Asia-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 4-3: Europe-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 4-4: Europe-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 4-5: North America-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 4-6: North America-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 5-1: Global-Cervical Cancer Test (Screening) Population Share (Percent) by Region, 2008-2015
  • Figure 5-2: Global-Forecast for Cervical Cancer Test (Screening) Population Share (Percent) by Region, 2016-2020
  • Figure 6-1: Global-Cervical Cancer Market Share (Percent) By Region, 2008-2015
  • Figure 6-2: Global-Forecast for Cervical Cancer Market Share (Percent) By Region, 2016-2020
  • Figure 7-1: United Kingdom-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 7-2: United Kingdom-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 7-3: United Kingdom-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 7-4: United Kingdom-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 7-5: United Kingdom-Cervical Cancer Deaths (Number), 2001-2011
  • Figure 7-6: United Kingdom-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 7-7: United Kingdom-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 7-8: United Kingdom-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 7-9: United Kingdom-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 7-10: United Kingdom-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 7-11: United Kingdom-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 8-1: France-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 8-2: France-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 8-3: France-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 8-4: France-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 8-5: France-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 8-6: France-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 8-7: France-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 8-8: France-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 8-9: France-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 8-10: France-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 8-11: France-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 9-1: Germany-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 9-2: Germany-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 9-3: Germany-Cervical Cancer HPV DNA Test Population (Thousand), 2005-2013
  • Figure 9-4: Germany-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2014-2020
  • Figure 9-5: Germany-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 9-6: Germany-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 9-7: Germany-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 9-8: Germany-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 9-9: Germany-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 9-10: Germany-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 9-11: Germany-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 10-1: Italy-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 10-2: Italy-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 10-3: Italy-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 10-4: Italy-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 10-5: Italy-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 10-6: Italy-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 10-7: Italy-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 10-8: Italy-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 10-9: Italy-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 10-10: Italy-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 10-11: Italy-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 11-1: Spain-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 11-2: Spain-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 11-3: Spain-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 11-4: Spain-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 11-5: Spain-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 11-6: Spain-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 11-7: Spain-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 11-8: Spain-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 11-9: Spain-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 11-10: Spain-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 11-11: Spain-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 12-1: Sweden-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 12-2: Sweden-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 12-3: Sweden-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 12-4: Sweden-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 12-5: Sweden-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 12-6: Sweden-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 12-7: Sweden-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 12-8: Sweden-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 12-9: Sweden-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 12-10: Sweden-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 12-11: Sweden-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 13-1: Switzerland-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 13-2: Switzerland-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 13-3: Switzerland-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 13-4: Switzerland-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 13-5: Switzerland-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 13-6: Switzerland-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 13-7: Switzerland-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 13-8: Switzerland-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 13-9: Switzerland-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 13-10: Switzerland-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 13-11: Switzerland-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 14-1: Norway-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 14-2: Norway-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 14-3: Norway-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 14-4: Norway-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 14-5: Norway-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 14-6: Norway-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 14-7: Norway-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 14-8: Norway-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 14-9: Norway-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 14-10: Norway-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 14-11: Norway-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 15-1: Netherlands-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 15-2: Netherlands-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 15-3: Netherlands-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 15-4: Netherlands-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 15-5: Netherlands-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 15-6: Netherlands-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 15-7: Netherlands-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 15-8: Netherlands-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 15-9: Netherlands-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 15-10: Netherlands-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 15-11: Netherlands-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 16-1: United States-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 16-2: United States-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 16-3: United States-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 16-4: United States-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 16-5: United States-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 16-6: United States-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 16-7: United States-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 16-8: United States-Pap smear Test Market (Million US$), 2008-2015
  • Figure 16-9: United States-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 16-10: United States-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 16-11: United States-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 17-1: Canada-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 17-2: Canada-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 17-3: Canada-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 17-4: Canada-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 17-5: Canada-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 17-6: Canada-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 17-7: Canada-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 17-8: Canada-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 17-9: Canada-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 17-10: Canada-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 17-11: Canada-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 18-1: Japan-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 18-2: Japan-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 18-3: Japan-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 18-4: Japan-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 18-5: Japan-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 18-6: Japan-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 18-7: Japan-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 18-8: Japan-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 18-9: Japan-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 18-10: Japan-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 18-11: Japan-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 19-1: Korea-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 19-2: Korea-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 19-3: Korea-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 19-4: Korea-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 19-5: Korea-Cervical Cancer Mortality (Number), 2001-2011
  • Figure 19-6: Korea-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 19-7: Korea-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 19-8: Korea-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 19-9: Korea-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 19-10: Korea-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 19-11: Korea-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 20-1: Singapore-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 20-2: Singapore-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 20-3: Singapore-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 20-4: Singapore-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 20-5: Singapore-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 20-6: Singapore-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 20-7: Singapore-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 20-8: Singapore-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 20-9: Singapore-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 20-10: Singapore-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 21-1: Malaysia-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 21-2: Malaysia-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 21-3: Malaysia-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 21-4: Malaysia-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 21-5: Malaysia-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 21-6: Malaysia-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 21-7: Malaysia-Pap smear Test Market (Million US$), 2008-2015
  • Figure 21-8: Malaysia-Forecast for Pap smear Test Market (Million US$), 2016-2020
  • Figure 21-9: Malaysia-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 21-10: Malaysia-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 22-1: India-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 22-2: India-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 22-3: India-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 22-4: India-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 22-5: India-Cervical Cancer VIA Test Population (Thousand), 2008-2015
  • Figure 22-6: India-Forecast for Cervical Cancer VIA Test Population (Thousand), 2016-2020
  • Figure 22-7: India-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 22-8: India-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 22-9: India-Pap smear Test Market (Million US$), 2008-2015
  • Figure 22-10: India-Forecast for Pap smear Test Market (Million US$), 2016-2020
  • Figure 22-11: India-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 22-12: India-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 22-13: India-VIA Test Market (Million US$), 2008-2015
  • Figure 22-14: India-Forecast for VIA Test Market (Million US$), 2016-2020
  • Figure 23-1: China-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 23-2: China-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 23-3: China-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 23-4: China-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 23-5: China-Cervical Cancer VIA Test Population (Thousand), 2008-2015
  • Figure 23-6: China-Forecast for Cervical Cancer VIA Test Population (Thousand), 2016-2020
  • Figure 23-7: China-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 23-8: China-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 23-9: China-Pap smear Test Market (Million US$), 2008-2015
  • Figure 23-10: China-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 23-11: China-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 23-12: China-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 23-13: China-VIA Test Market (Million US$), 2008-2015
  • Figure 23-14: China-Forecast for VIA Test Market (Million US$), 2016-2020
  • Figure 24-1: Thailand-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 24-2: Thailand-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 24-3: Thailand-Cervical Cancer VIA Test Population (Thousand), 2008-2015
  • Figure 24-4: Thailand-Forecast for Cervical Cancer VIA Test Population (Thousand), 2016-2020
  • Figure 24-5: Thailand-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 24-6: Thailand-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 24-7: Thailand-Pap smear Test Market (Million US$), 2008-2015
  • Figure 24-8: Thailand-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 24-9: Thailand-VIA Test Market (Million US$), 2008-2015
  • Figure 24-10: Thailand-Forecast for VIA Test Market (Million US$), 2016-2020
  • Figure 25-1: Indonesia-Cervical Cancer Pap Smear Test Population (Thousand), 2008-2015
  • Figure 25-2: Indonesia-Forecast for Cervical Cancer Pap Smear Test Population (Thousand), 2016-2020
  • Figure 25-3: Indonesia-Cervical Cancer HPV DNA Test Population (Thousand), 2008-2015
  • Figure 25-4: Indonesia-Forecast for Cervical Cancer HPV DNA Test Population (Thousand), 2016-2020
  • Figure 25-5: Indonesia-Cervical Cancer VIA Test Population (Thousand), 2008-2015
  • Figure 25-6: Indonesia-Forecast for Cervical Cancer VIA Test Population (Thousand), 2016-2020
  • Figure 25-7: Indonesia-Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2008-2015
  • Figure 25-8: Indonesia-Forecast for Cervical Cancer Both (Pap Smear & VIA) Test Population (Thousand), 2016-2020
  • Figure 25-9: Indonesia-Cervical Cancer Test Market (Million US$), 2008-2015
  • Figure 25-10: Indonesia-Forecast for Cervical Cancer Test Market (Million US$), 2016-2020
  • Figure 25-11: Indonesia-Pap Smear Test Market (Million US$), 2008-2015
  • Figure 25-12: Indonesia-Forecast for Pap Smear Test Market (Million US$), 2016-2020
  • Figure 25-13: Indonesia-HPV DNA Test Market (Million US$), 2008-2015
  • Figure 25-14: Indonesia-Forecast for HPV DNA Test Market (Million US$), 2016-2020
  • Figure 25-15: Indonesia-VIA Test Market (Million US$), 2008-2015
  • Figure 25-16: Indonesia-Forecast for VIA Test Market (Million US$), 2016-2020
  • Figure 25-17: Indonesia-Both (Pap smear & VIA) Test Market (Million US$), 2008-2015
  • Figure 25-18: Indonesia-Forecast for Both (Pap Smear & VIA) Test Market (Million US$), 2016-2020

List of Tables:

  • Table 5-1: Global -Cervical Cancer Test Population Share (Percent) By Country, 2008-2015
  • Table 5-2: Global-Forecast for Cervical Cancer Test Population Share (Percent) by Country, 2016-2020
  • Table 6-1: Global-Cervical Cancer Test Market Share (Percent) by Country, 2008-2015
  • Table 6-2: Global-Forecast for Cervical Cancer Test Market Share (Percent) by Country, 2016-2020
  • Table 6-3: Global-Pap Smear Test Market Share (Percent), 2008-2015
  • Table 6-4: Global-Forecast for Pap Smear Test Market Share (Percent), 2016-2020
  • Table 6-5: Global-HPV DNA Test Market Share (Percent), 2008-2015
  • Table 6-6: Global-Forecast for HPV DNA Test Market Share (Percent), 2016-2020
  • Table 6-7: Global-VIA Test Market Share (Percent), 2008-2015
  • Table 6-8: Global-Forecast for VIA Test Market Share (Percent), 2016-2020
  • Table 26-1: Worldwide-List of Countries which offer VIA Test via National Programs, 2015
  • Table 26-2: Worldwide-List of Countries which offer VIA Test via Pilot Programs, 2015
  • Table 26-3: Worldwide-Prevalence of HPV 16/18 in Women with Normal Cervical Cytology (Percent), 2014-2015
  • Table 26-4: United Kingdom-Number of Incidence Observed and Projected and their respective Age Standardized Rate, 2010-2025
  • Table 26-5: Worldwide-Prevalence (Percent) of Young Women (15-44 Years) who Have Sex before the Age of 15 Years, 1994-2006
Back to Top